Back to results
US 10,214,590 B2Granted
Inhibitors of endoglin activity for the treatment of fibrosis
AssigneeTufts Medical Center, Inc.
InventorsNavin K. Kapur, Richard H. Karas
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeTufts Medical Center, Inc.
InventorsNavin K. Kapur, Richard H. Karas
Estimating the term…
Endoglin has been identified to play a functional role as a regulator of TGFβ1 signaling, particular in TGFβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGFβ1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.
A method of treating a fibrotic disease in a human subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a composition comprising an antibody or antigen-binding fragment thereof that binds endoglin and inhibits endoglin activity, wherein the fibrotic disease is selected from the group consisting of lung fibrosis, kidney fibrosis, and liver fibrosis.
Dependencies are inferred from the claim text.